Research Highlight: Critical multiple angiogenic factors by glioblastoma stem-like cells underline the need for combinatorial anti-angiogenic therapeutic strategies

ENP researcher Hervé Chneiweiss and his colleagues recently reviewed information on the angiogenic factors that are secreted by glioblastoma stem cells, and they argue that there is a need for anti-angiogenic therapies that target those factors. They point to new findings that Semaphorin 3a and hepatoma-derived growth factor, two molecules released by glioblastoma stem cells, present the opportunity for novel therapies that can diminish vasculature to the glioblastoma.

Check out the article for more details:

Cécile Thirant, Julie Gavard, Marie-Pierre Junier, and Hervé Chneiweiss. Critical multiple angiogenic factors by glioblastoma stem-like cells underline the need for combinatorial anti-angiogenic therapeutic strategies. Proteomics Clin Appl. 2013. 7: 79-90.

 

Keywords: Anti-angiogenic Endothelial cell Glioblastoma stem-like cells HDGF Therapeutic resistance

Figure 1A from Thirant et al., Proteomics Clin App, 2013. Figure shows a glioblastoma outlined in the brain of a patient.